Organisation paid for research Program year 2019 Source: CMS Open Payments

Center for Clinical Studies LLC

Neither a doctor nor a teaching hospital

Research payments

$803,766

15 payments

Through program year 2019, Center for Clinical Studies LLC is reported as receiving $803,766 in research payments, across 15 payments.

By program year

1 row
Year Kind Amount Payments
2019 Research $803,766 15

Breakdown

Who paid Research payments · program year 2019
  1. Ucb SA $736,802 11 payments
  2. UCB Biosciences Inc. $61,488 3 payments
  3. Merck Sharp & Dohme Corporation $5,476 1 payment
Studies the money was for Research payments · program year 2019
  1. A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis. $372,303 2 payments
  2. A Phase 3, Multicenter, Randomized, Double-Blind Study With A 24-Week Active-Controlled Initial Treatment Period Followed By A 32-Week, Dose-Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis $206,964 3 payments
  3. A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed By A Dose-Blind Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis $86,710 1 payment
  4. A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis $61,488 3 payments
  5. A Phase 3 Multicenter, randomized, double-blind, placebo - and active comparator-controlled, parallel group study to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis $48,199 3 payments
  6. A Multicenter, 48-Week, Doubleblind, Placebo Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Phase 2B $22,628 2 payments
  7. A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety,Tolerability of Subcutaneous SCH 900222,MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis Protocol No. MK-3222-010 $5,476 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2019

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record